Drugs / BEVIFIMOD
BEVIFIMOD
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01749787 | Nov 2012 → Aug 2014 | rheumatoid arthritis | Protalex, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00571467 | Dec 2007 → Mar 2009 | autoimmune thrombocytopenic purpura | Protalex, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00517855 | Jun → Sep 2007 | — | Protalex, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02566603 | Nov 2015 → May 2018 | thrombocytopenia due to immune destruction | Protalex, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02401061 | Sep 2015 → Mar 2019 | autoimmune thrombocytopenia | Protalex, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02330445 | Feb 2015 → Apr 2016 | rheumatoid arthritis | Protalex, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEVIFIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298076 ↗ |
| Known as | Iggsorb | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298076 ↗ |
| Known as | Pansorbin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298076 ↗ |
| Known as | Protein a | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298076 ↗ |
| Known as | PRTX-100 | “PRTX-100” NCT00571467 ↗ |
| Known as | Staphylococcal protein A | “PRTX-100 (Staphylococcal protein A)” NCT00571467 ↗1“PRTX-100 (Staphylococcal protein A)” NCT00517855 ↗ |
| Modality | Protein / enzyme biologic | “PRTX-100 (Staphylococcal protein A)” NCT00571467 ↗ |
| Route | Intravenous | “single intravenous (IV) dose of PRTX-100” NCT00517855 ↗ |